139 related articles for article (PubMed ID: 17473922)
1. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Chung F; Liu J; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
3. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
5. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
Kestell P; Zhao L; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM
Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
Baguley BC; Zhuang L; Kestell P
Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186
[TBL] [Abstract][Full Text] [Related]
8. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cao Z; Baguley BC; Ching LM
Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
[TBL] [Abstract][Full Text] [Related]
10. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule cytokine inducers causing tumor necrosis.
Baguley BC
Curr Opin Investig Drugs; 2001 Jul; 2(7):967-75. PubMed ID: 11757800
[TBL] [Abstract][Full Text] [Related]
12. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Woon ST; Baguley BC; Palmer BD; Fraser JD; Ching LM
Oncol Res; 2002; 13(2):95-101. PubMed ID: 12392157
[TBL] [Abstract][Full Text] [Related]
13. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
[TBL] [Abstract][Full Text] [Related]
14. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
16. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Zhao L; Kestell P; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.
Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):186-92. PubMed ID: 12203100
[TBL] [Abstract][Full Text] [Related]
19. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Zhou S; Kestell P; Tingle MD; Ching LM; Paxton JW
Cancer Chemother Pharmacol; 2001 Jun; 47(6):541-4. PubMed ID: 11459209
[TBL] [Abstract][Full Text] [Related]
20. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
